- Shoppers Drug Mart report: Allowing pharmacists in Canada to immunize could save lives, money
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- CDC: Flu vaccination prevented an estimated 6.6 million influenza-associated illnesses last season
- Study: GSK’s FluLaval Quadrivalent reduces flu cases among children ages 3 years to 8 years by 55.4%
- CDC: Flu season past its peak but still going strong
LONDON — The Food and Drug Administration has approved a vaccine made by GlaxoSmithKline that protects against four strains of the flu, the drug maker said.
GSK announced the approval of Flulaval Quadrivalent (influenza virus vaccine) in patients aged 3 years and older for protecting against two strains of the A and B strains of the virus; quadrivalent refers to the four strains the vaccines protect against, as opposed to three-strain trivalent vaccines. The FDA also approved GSK's Fluarix Quadrivalent in December 2012, and the company received FDA approval for shipment of that vaccine earlier this month.
"Since the late 1980s, public health authorities have known that four primary influenza strains circulate each year, causing the majority of influenza illness, but the influenza vaccines used for the past 30 years only covered against three strains," GSK Vaccines North America director of scientific affairs and public health Leonard Friedland said. "With this limitation, global influenza experts have had to make a difficult determination around the strains each season to cover, and in six of the past 11 influenza seasons, one of the predominant strains was not included in the season's influenza vaccines."
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.